These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2496221)

  • 21. Correlation viability/morphology in Mycobacterium leprae.
    Silva MT; Macedo PM; Portaels F; Pattyn SR
    Acta Leprol; 1984; 2(2-4):281-91. PubMed ID: 6398588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electron microscopic observations of cell division in Mycobacterium leprae by means of serial ultrathin sectioning.
    Hirata T
    Int J Lepr Other Mycobact Dis; 1978; 46(2):160-6. PubMed ID: 355158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Degradation process of Mycobacterium leprae cells in infected tissue examined by the freeze-substitution method in electron microscopy.
    Amako K; Takade A; Umeda A; Matsuoka M; Yoshida S; Nakamura M
    Microbiol Immunol; 2003; 47(6):387-94. PubMed ID: 12906098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dapsone resistance does not appear to be associated with a mutation in the dihydropteroate synthase-2 gene of Mycobacterium leprae.
    Gillis TP; Williams DL
    Indian J Lepr; 1999; 71(1):11-8. PubMed ID: 10439322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A rapid method for viability and drug sensitivity of Mycobacterium leprae cultured in macrophages and using fluorescein diacetate.
    Bhagria A; Mahadevan PR
    Indian J Lepr; 1987; 59(1):9-19. PubMed ID: 2440960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary and secondary dapsone resistance of M. leprae in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985.
    Guelpa-Lauras CC; Cartel JL; Constant-Desportes M; Millan J; Bobin P; Guidi C; Brucker G; Flageul B; Guillaume JC; Pichet C
    Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4):672-9. PubMed ID: 3323369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibilities of Mycobacterium leprae and M. avium complex to the H2O2-Fe-mediated halogenation system supplemented with antimicrobial agents.
    Tomioka H; Yamada Y; Saito H; Jidoi J
    Int J Lepr Other Mycobact Dis; 1989 Sep; 57(3):628-32. PubMed ID: 2476523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of ascorbic acid in inhibiting the multiplication of M. leprae in the mouse foot pad.
    Hastings RC; Richard V; Christy SA; Morales MJ
    Int J Lepr Other Mycobact Dis; 1976; 44(4):427-30. PubMed ID: 798727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of freezing and thawing on the viability and the ultrastructure of in vivo grown mycobacteria.
    Portaels F; Fissette K; De Ridder K; Macedo PM; De Muynck A; Silva MT
    Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):580-7. PubMed ID: 3065421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of sodium hydroxide and trypsin on the viability of Mycobacterium leprae.
    Matsuo Y
    Hiroshima J Med Sci; 1974 Mar; 23(1):19-23. PubMed ID: 4611983
    [No Abstract]   [Full Text] [Related]  

  • 31. Clarithromycin is bactericidal against strains of Mycobacterium leprae resistant and susceptible to dapsone and rifampin.
    Walker LL; Van Landingham RM; Shinnick TM
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):59-65. PubMed ID: 8326182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined rifampin and dapsone chemotherapy of Mycobacterium leprae infection of the neonatally thymectomized Lewis rat.
    Fieldsteel AH; Levy L
    Int J Lepr Other Mycobact Dis; 1980 Sep; 48(3):267-76. PubMed ID: 7002811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of brodimoprim on Mycobacterium leprae in vitro and in mouse foot-pads.
    Dhople AM; Ortega I; Seydel JK; Gardner GD
    Indian J Lepr; 1990; 62(1):76-86. PubMed ID: 2193064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of potassium tellurite and ATP content in Mycobacterium leprae.
    David HL; Rastogi N; Frehel C; Gheorghiu M
    Ann Microbiol (Paris); 1982; 133(1):129-39. PubMed ID: 7051925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An in vitro culture method for screening new drugs against Mycobacterium leprae.
    Dhople AM; Ortega I
    Indian J Lepr; 1990; 62(1):66-75. PubMed ID: 2193063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uptake of purine and pyrimidine nucleosides by macrophage-resident Mycobacterium leprae: 3H-adenosine as an indicator of viability and antimicrobial activity.
    Harshan KV; Mittal A; Prasad HK; Misra RS; Chopra NK; Nath I
    Int J Lepr Other Mycobact Dis; 1990 Sep; 58(3):526-33. PubMed ID: 2205687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against Mycobacterium leprae.
    Dhople AM
    Int J Antimicrob Agents; 2002 Jan; 19(1):71-4. PubMed ID: 11814771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mouse foot pad growth of M. leprae in relation to bacteriological index.
    Bhatia VN; Balakrishnan S; Venkataramaniah HN; Harikrishnan S
    Lepr India; 1983 Apr; 55(2):247-51. PubMed ID: 6355651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavior of Mycobacterium leprae in human macrophages in vitro.
    Samuel DR; Godal T; Myrvang B; Song YK
    Infect Immun; 1973 Sep; 8(3):446-9. PubMed ID: 4581011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenosine triphosphate content of Mycobacterium leprae from leprosy patients.
    Dhople AM
    Int J Lepr Other Mycobact Dis; 1984 Jun; 52(2):183-8. PubMed ID: 6373626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.